Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state

This bill expands New York State's newborn screening program to include five additional rare genetic conditions: CLN2, MPS IVA, MPS VI, MPS VII, and Fabry disease. The legislation directly affects newborns in New York by requiring healthcare providers to test for these conditions shortly after birth, enabling earlier diagnosis and treatment. The bill achieves this by amending the state's public health law to add these specific diseases to the official screening panel. This change ensures that infants at risk for these treatable conditions can receive timely medical intervention. The law takes effect immediately upon passage.